NovoCure (NVCR) Net Cash Flow (2014 - 2026)

NovoCure has disclosed Net Cash Flow across 13 years of filings, most recently posting -$5.9 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$5.9 million, up 83.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$32.1 million (up 90.2% YoY), and the FY2025 annual result was -$63.1 million, up 17.3% from the prior year.
• Net Cash Flow came in at -$5.9 million for Q1 2026 at NovoCure, up from -$241.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $214.9 million in Q1 2024 to a low of -$288.8 million in Q2 2024.
• The 5-year median for Net Cash Flow is -$5.9 million (2026), against an average of -$6.6 million.
• Across the five-year window, Net Cash Flow soared 2435.48% in 2024 and plunged 949.62% in 2025, its largest moves.
• NovoCure's Net Cash Flow stood at -$128.4 million in 2022, then jumped by 166.89% to $85.9 million in 2023, then tumbled by 126.76% to -$23.0 million in 2024, then slumped by 949.62% to -$241.2 million in 2025, then jumped by 97.54% to -$5.9 million in 2026.
• The last three Net Cash Flow figures came in at -$5.9 million (Q1 2026), -$241.2 million (Q4 2025), and $192.5 million (Q3 2025), per Business Quant data.